New 52 Week low stocks in US (PANL, BCRX, OSUR, CORT)

New York, NY -- (SBWIRE) -- 11/08/2012 -- Universal Display Corporation (NASDAQ:PANL) is engaged in the research, development and commercialization of organic light emitting diode (OLED) technologies and materials. OLEDs are thin, lightweight and solid-state devices that emit light, making them suitable for use in full-color displays and as lighting products. Universal Display Corp (NASDAQ:PANL) 25% LOWER; reported Q3 EPS of ($0.12), $0.17 worse than the analyst estimate of $0.05. Revenue for the quarter came in at $12.5 million versus the consensus estimate of $18.87 million. Universal Display Corp sees FY2012 revenue of $80-82 million, versus prior guidance of $90-110 million and the consensus of $99.8 million.

Get Free Trend Analysis On PANL Here

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX -40.41%)today announced completion of the planned interim analysis of the peramivir Phase 3 trial in patients admitted to the hospital with serious influenza. The difference between peramivir and control groups for the primary endpoint was small and the recalculated sample size was greater than the predefined futility boundary of 320 subjects. Based on this information, the independent data monitoring committee (DMC) recommended that the study be terminated for futility. No unexpected adverse events were identified and the DMC expressed no concerns about the safety of peramivir. Shares of BioCryst Pharmace (NASDAQ:BCRX) are trading at $1.40 and is -66.20% of its 50-day Moving Average price of $4.1421 and -64.51% from its 200-day Moving Average price of $3.9442. The average trading volume is 275119 shares and its market capitalization is $70.7M.

How Should Investors Trade BCRX Now? Find Out Here

OraSure Technologies, Inc. involve in the development, manufacture, marketing and sale of oral fluid diagnostic products and specimen collection devices using its proprietary oral fluid technologies. OraSure Technologies (NASDAQ:OSUR) announced its earnings results on Wednesday. The company reported ($0.04) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.07) by $0.03. The company had revenue of $22.10 million for the quarter, compared to the consensus estimate of $22.26 million. During the same quarter in 2011, the company posted ($0.03) earnings per share. OraSure Technologies’s revenue was up 1.8% compared to the same quarter last year.

Will OSUR Rebound After Today’s Slump? Find Out Here

Corcept Therapeutics Incorporated (NASDAQ:CORT) is a pharmaceutical company engaged in the discovery and development of drugs for the treatment of severe metabolic and psychiatric disorders. The Company focuses on the disorders that are associated with a steroid hormone called cortisol. CORT reported EPS of -0.414. For the Current Fiscal year, the company is expected to report EPS of -0.35. For the Next Quarter and Next Year, the company is expected to report EPS of -0.08 and -0.27 respectively. At Current Market Price, CORT is in distance of -41.90% from its 50-day Moving Average price of $2.5644 and -56.62% from its 200-day Moving Average price of $3.4347.

For a FREE INSTANT ANALYSIS of CORT, Please Visit Here

DISCLAIMER
Neither PennyStocksUpdate.biz nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor or broker dealer in any jurisdiction whatsoever and none of the information provided by PennyStocksUpdate.biz, owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or an investment recommendation.PennyStocksUpdate.biz makes no recommendation that the securities of the companies profiled should be purchased, sold or held by individuals or entities that learn of the profiled companies through PennyStocksUpdate.biz. Investing in securities is speculative and carries a high degree of risk and no investment should be made unless you can afford to lose your entire investment. It is possible that an investor's entire investment may be lost or impaired due to the speculative nature of the companies profiled. Please consult a broker before purchasing or selling any securities viewed on or mentioned here in..

Contact:
PennyStocksUpdate.biz
info@pennystocksupdate.biz